All Industry Symposia

Saturday, 6 June 2020

CSS 1

10.30-11.45

Sanofi Genzyme / Regeneron
Type 2 Inflammation in Atopic Dermatitis and Beyond: Shared Pathophysiology and Clinical Management

Welcome and Introduction
Marcus Maurer, Germany

Shared Pathophysiology and Epidemiology of Atopic Dermatitis with Other Type 2 Inflammatory Diseases
Marcus Maurer, Germany

Clinical Management of Atopic Dermatitis and Other Type 2 Inflammatory Diseases
Miriam Wittmann, United Kingdom

Panel Q&A
All faculty

CSS2
12.00-13.15

MSD
Chronic Cough; What Allergists Need to Know

Chair: Joaquin Sastre, Spain

Welcome and Opening Remarks:
Chronic cough and the allergist
Joaquin Sastre, Spain

What is the mechanism of chronic cough and the burden on patients and their subsequent journey through the Healthcare System?
Jaclyn Ann Smith, United Kingdom

Which are the main causes of chronic cough and how to best diagnose and treat them
Michael Blaiss, United States

Q&A via Chat
All faculty

CSS 3

Novartis Pharma AG
Targeting IgE: what does it mean for patients, especially during this COVID-19 crisis?

Chair: Nikolaos Papadopoulos, United Kingdom

Perspectives and new findings on asthma and comorbidity management: what to EXPECT
Marc Humbert, France

Q&A
Nikolaos Papadopoulos, United Kingdom
Marc Humbert, France

Omalizumab in chronic spontaneous urticaria, be AWARE
Ana Maria Giménez-Arnau, Spain

Roundtable discussion
All faculty

CSS5

16.30-17.45

Sanofi Genzyme / Regeneron
Dupilumab: Bridging Innovation in Biologic Treatment Across Type 2 Inflammatory Airway Diseases

Chair: William W. Busse, United States

Opening Remarks: Type 2 Inflammation in Airway Disease
William W. Busse, United States

Clinical Trial Evidence for Dupilumab in Patients With CRSwNP
Claus Bachert, Belgium

Patient Selection and Management Approaches in CRSwNP
Claus Bachert, Belgium

Dupilumab Clinical Insights in Type 2 Inflammatory Airway Diseases
Raffi Tachdjian, United States

Closing Remarks
William W. Busse, United States

Sunday, 7 June 2020

CSS 7
10.30-11.45

Nestlé Health Science
New Advances in the Prevention and Management of Food Allergy

Chair: Yvan Vandenplas, Belgium

Nutritional Strategies for Food Allergy Prevention
Carina Venter, United States

Human Milk Oligosaccharides (HMO) for the Immune System Development
Norbert Sprenger, Switzerland

New data on the Benefits of HMO in the Management of Cow’s Milk Protein Allergy
Anna Nowak-Wegrzyn, United States

CSS 8

12.00-13.15

DBV TECHNOLOGIES
Life with Peanut allergy: What is the potential role of investigational Viaskin Peanut?

Chairs:
Helen Brough, United Kingdom
Susanne Lau, Germany

Introduction
Susanne Lau, Germany

The psycho-social impact of peanut allergy for children and their families
Antonella Muraro, Italy

Can the increase in threshold of eliciting doses help peanut allergic subjects?
Graham Roberts, United Kingdom

Investigational Viaskin Peanut clinical trial data: efficacy, safety, practicality
Lars Lange, Germany

Conclusion
Helen Brough, United Kingdom

CSS9

13.30-14.00

Sanofi Genzyme / Regeneron
Scoping CRSwNP: Putting the Spotlight on Type 2 Inflammation

Chair: Peter Hellings, Belgium

Evaluating CRSwNP Burden: A Closer Look at the Patient Experience
Peter Hellings, Belgium

Type 2 Inflammation as the Key Driver of CRSwNP Pathophysiology
Peter Hellings, Belgium

Treating CRSwNP: Evolving the Therapeutic Space With Biologics
Claus Bachert, Belgium

CSS 10

15.00-16.15

STALLERGENES GREER
Overcoming challenges in 2020: Bringing a positive outlook to allergic patients’ horizons

Chair: Ludger Klimek, Germany

COVID-19 Pandemic: AIT positioning in respiratory allergy
Walter Canonica, Italy

Childhood AR and Asthma and development patterns of lung function
Adnan Custovic, United Kingdom

Shaping the horizons of allergic patients
Philippe Gevaert, Belgium

Expert panel discussion – Q&A Chat

CSS 11

16.30-17.45

GSK
Mepolizumab: Targeting eosinophils in children and adults with severe eosinophilic asthma (SEA)

Chair: Neil Martin, United Kingdom

Welcome address from chair
Neil Martin, United Kingdom

An expert view of SEA in patients of all ages
Peter Gibson, Australia

Latest mepolizumab data: Long-term and real-world evidence in adults
Stephanie Korn, Germany

Building on the foundation of mepolizumab: Data in paediatric patients
Atul Gupta, United Kingdom

Expert opinion: Clinical cases in patients with SEA
Liam Heaney, United Kingdom
Peter Gibson, Australia
Stephanie Korn, Germany
Atul Gupta, United Kingdom
Neil Martin, United Kingdom

Closing remarks
Neil Martin, United Kingdom

Live chat Q&A
All faculty

CSS 12

18.00-19.15

Sanofi Genzyme / Regeneron
Type 2 Inflammation and Role of Key Mediators in the Clinical Hallmarks of Uncontrolled Severe Asthma

Chair: Leonard B. Bacharier, United States

Welcome and Opening Remarks
Leonard B. Bacharier, United States
Michael Wechsler, United States

Defining Control and Type 2 Inflammation in Severe Asthma
Michael Wechsler, United States

Elucidating the Roles Key Cytokines Play in Clinical Manifestations of Severe Asthma
Leonard B. Bacharier, United States

Applying Understanding of Type 2 Inflammation in Clinical Practice
All faculty

Closing / Q&A
All faculty

Monday, 8 June 2020

CSS 14

12.00-13.15

Novartis Pharma AG
Breakthrough in the understanding of the anti-IgE pathway in CSU

Chairs:
Marcus Maurer, Germany
Alexander Eggel, Switzerland

Introduction to CSU
Marcus Maurer, Germany

IgE inhibition in CSU: Not all anti-IgEs are born equal
Alexander Eggel, Switzerland

IgE inhibition implications: How does this benefit patients with CSU?
Marcus Maurer, Germany

Q&A
Marcus Maurer, Germany
Alexander Eggel, Switzerland

CSS17

18.00-19.15

LETIPharma
AIT beyond pollens and mites. A future of opportunities.

Chair: Ralph Mösges, Germany